ClearPoint Neuro, Inc. CLPT

ClearPoint Neuro (NASDAQ:CLPT) shares fell 24% on Tuesday following updated clinical trial results from partner uniQure N. V.

Price targets for ClearPoint Neuro have shifted toward the low to mid US$20s, with the average assessed fair value moving from US$28.33 to US$23.50 and one outlier still at US$30. Analysts link this change to a period they see as more investment heavy, balancing optimism about long term growth potential with caution around near term execution and partner related contributions. As you read on, you will see how this evolving narrative could shape the way you track ClearPoint Neuro from...

Moby summary of ClearPoint Neuro, Inc.'s Q2 2026 earnings call

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -31.03% and -16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, ...

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) ...

OPKO Health (OPK) delivered earnings and revenue surprises of +87.50% and +24.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release ...

ClearPoint Neuro (NASDAQ:CLPT) surged 50% on Wednesday after partner company UniQure announced a significant regulatory milestone for its Huntington’s disease treatment candidate, AMT-130. Investors responded positively to the update, which could accelerate development of a therapy that relies on ClearPoint’s technology platform for delivery.

Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint ...

ClearPoint Neuro’s fair value estimate has been trimmed from US$25.00 to US$22.00, roughly a 12% reduction in the modeled price target. Analysts link this reset to a balance of optimism around more than 60 biopharma partnerships and expedited intracranial programs, as well as caution tied to recent FDA feedback and its impact on revenue assumptions. As you read on, you will see how this evolving narrative could influence how you track the stock and its key milestones over time. Analyst Price...

ClearPoint Neuro Inc (CLPT) reports a 43% revenue increase and strategic advancements despite rising operational costs.